Home Report Catalogue APAC Precision Oncology Market Analysis
Pharmaceuticals APAC

APAC Precision Oncology Market Analysis, 2024–2034

APAC Precision Oncology Market Industry Trends and Forecast to 2034: Segmented by (Product, Cancer, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

APAC · 2024–2034 · estimates

Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $20.23 Bn Estimated value
Estimate 2025 $22.50 Bn 19.6% of the global market
Projected 2034 $58.50 Bn 160% Adds $36.00 Bn over 9 forecast years
CAGR 2025–2034 11.2% Faster than 61% of 180 Pharmaceuticals markets here
Key players 5
  • APAC is 19.57% of the global market.
  • Among regions, the largest is North America at $59.45 Bn.
  • Fastest growing: Africa at 11.3% a year.
  • APAC ranks 3rd of 6 by size among regions.

Market size projection

APAC

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$36.00 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Precision Oncology Market market size by year, APAC
YearMarket sizeChange that yearSince 2025
2024 (estimate) $20.23 Bn — —
2025 (base) $22.50 Bn +$2.27 Bn —
2026 (forecast) $25.02 Bn +$2.52 Bn +11.2%
2027 (forecast) $27.82 Bn +$2.80 Bn +23.7%
2028 (forecast) $30.94 Bn +$3.12 Bn +37.5%
2029 (forecast) $34.40 Bn +$3.47 Bn +52.9%
2030 (forecast) $38.26 Bn +$3.85 Bn +70%
2031 (forecast) $42.54 Bn +$4.28 Bn +89.1%
2032 (forecast) $47.31 Bn +$4.76 Bn +110.2%
2033 (forecast) $52.61 Bn +$5.30 Bn +133.8%
2034 (forecast) $58.50 Bn +$5.89 Bn +160%

Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $114.95 Bn
  2. North America $59.45 Bn
  3. US $46.76 Bn
  4. Europe $22.70 Bn
  5. APAC (this report) $22.50 Bn
  6. Canada $10.53 Bn
  7. China $10.57 Bn
  8. Japan $8.11 Bn
  9. Latin America $6.03 Bn
  10. Middle East $5.12 Bn
  11. Germany $4.66 Bn
  12. Italy $3.08 Bn
  13. Brazil $3.15 Bn
  14. UK $2.98 Bn
  15. France $2.72 Bn
  16. India $2.49 Bn
  17. Spain $2.31 Bn
  18. Ecuador $2.31 Bn
  19. Saudi Arabia $1.97 Bn
  20. Africa $1.93 Bn
  21. Mexico $1.67 Bn
  22. New Zealand $1.28 Bn
  23. Australia $1.28 Bn
  24. Russia $1.10 Bn
  25. South Africa $676.5 Mn
  26. UAE $548.9 Mn
  27. Egypt $377.9 Mn
  28. Philippines $254.8 Mn
  29. Malaysia $181.0 Mn
  30. Hong Kong $169.5 Mn
  31. Singapore $139.6 Mn
  32. Thailand $123.8 Mn
  33. Kenya $90.3 Mn

The APAC Precision Oncology Market Analysis Executive Summary

Precision oncology matches cancer treatment to the genetic changes in a patient's tumour, using tests and targeted drugs.

Key segments of the precision Oncology market include product (Genomic Tests, Targeted Therapies and Informatics Platforms) and cancer (Lung, Breast and Colorectal).

APAC Precision Oncology Market Dynamics

Market Growth Drivers

Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the precision Oncology market. Faster approvals and new combinations are improving survival.

Opportunity

Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the precision Oncology market.

Market Restraints

High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the precision Oncology market, especially in low- and middle-income countries.

Competitive Landscape for Precision Oncology Market in APAC

The precision Oncology market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Precision Oncology Market in APAC

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for precision Oncology. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in APAC.

Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Precision Oncology in APAC? Our analysts can size it for your plan. Talk to us See the public data Early deaths from long-term diseases (WHO) for every country, free. Open the Public Health Dashboard

From our blog

Brain Cancer Diagnosis: Imaging and New BiomarkersAbout 321,000 people were diagnosed with brain and nervous system tumours in 2022, and about 248,000 died… Bioinformatics: Making Sense of Health DataSequencing a human genome fell from about $50 million in 2003 to under $1,500 by late 2015. Bioinformatics… Dermatology Diagnostics: AI and Skin HealthSkin cancers caused over 1.5 million new cases in 2022. Imaging and AI tools are changing how skin conditions…
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in APAC

See all
Same topic, other categories

Related on oncology and genomics

See the topic